Rapid progression of hepatocellular carcinoma in a patient with autoimmune hepatitis

Internal Medicine

Volumn 50, Issue 13, 2011, Pages 1409-1413

  Yamamoto, Kayo ^a   Hiura, Masaaki ^a   Tabaru, Akinari ^a   Honma, Yuichi ^a   Narita, Ryoichi ^a   Abe, Shintaro ^a   Shimajiri, Shohei ^a   Okamoto, Kohji ^a   Yamaguchi, Koji ^a   Harada, Masaru ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Autoimmune hepatitis; Hepatocellular carcinoma; Ki67

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G; KI 67 ANTIGEN; PREDNISOLONE; PROTHROMBIN; URSODEOXYCHOLIC ACID; VITAMIN K GROUP;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CANCER GROWTH; CANCER SURGERY; CASE REPORT; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LIVER CELL CARCINOMA; PLASMA CELL; PROTEIN BLOOD LEVEL;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER NEOPLASMS; TIME FACTORS;

EID: 79960050799     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4873     Document Type: Article

References (23)

1. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36: 479-497, 2002.
2. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48: 169-176, 2008.
3. Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 31: 771-787, 2010.
4. Marrero CR, Marrero JA. Viral hepatitis and hepatocellular carcinoma. Arch Med Res 38: 612-620, 2007.
5. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol 35: 79-85, 2002.
6. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 52: 252-257, 2010.
7. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular car-cinoma--epidemiological trends and risk factors. Dig Dis 27: 80-92, 2009.
8. Cavazza A, Caballeria L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 50: 1162-1168, 2009.
9. Yamagishi Y, Horie Y, Kajihara M, et al. Hepatocellular carcinoma in heavy drinkers with negative markers for viral hepatitis. Hepa-tol Res 28: 177-183, 2004.
10. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 45: 86-94, 2010.
11. Park SZ, Nagorney DM, Czaja AL. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 45: 1944-1948, 2000.
12. Yeoman AD, Al-Chalabi T, Karani JB, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatol-ogy 48: 863-870, 2008.
13. Teufel A, Weinmann A, Centner C, et al. Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroen-terol 15: 578-582, 2009.
14. Miyake Y, Iwasaki Y, Terada R, et al. Persistant elevation of serum alanine aminotransferase levels leads to poor survival an hepato-cellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 24: 1197-1205, 2006.
15. Wong RJ, Gish R, Frederick K, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 56: 578-585, 2011.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005.
17. Montano-Loza A, Carpenter HA, Czaja AL. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 103: 1944-1951, 2008.
18. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929-938, 1999.
19. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fi-brosis in chronic hepatitis C. Hepatology 38: 1449-1457, 2003.
20. Fanning L, Loane J, Kenny-Walsh E, et al. Tissue viral load variability in chronic hepatitis C. Am J Gastroenterol 96: 3384-3389, 2001.
21. Takahashi K, Saijo N, Kimata M, et al. Suppression of natural killer activity in patients treated with cisplatin and methylpredniso-lone. J Cancer Res Clin Oncol 109: 78-81, 1985.
22. Korangy F, Hochst B, Manns MP, Greten TF. Immune responses in hepatocellular carcinoma. Dig Dis 28: 150-154, 2010.
23. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17: 470-474, 1999.